Xiaodong Liu

Xiaodong Liu

Auto-generated profile, based on publicly available information

Xiaodong Liu

Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2024 in BMC Medicine
Verified
Journal Article
Open access
PDF file
DLDavid Tak Wai Lui
David Tak Wai Lui
LLLanlan Li
Lanlan Li
XLXiaodong Liu
Xiaodong Liu
XXXi Xiong
Xi Xiong
ETEric Ho Man Tang
Eric Ho Man Tang
KTKathryn Choon Beng Tan
Kathryn Choon Beng Tan
Background: High levels of high-density lipoprotein cholesterol (HDL-C) are previously considered protective against cardiovascular diseases (CVD), but recent studies suggest an increased risk of adverse events at very high HDL-C levels in the general population. It remains to be elucidated such a relationship in diabetes, a condition with high cardiovascular risks. We examined the association of HDL-C levels with the risk of major adverse cardiovascular events (MACE) and mortality in type 2 diabetes. Methods: This retrospective cohort study identified individuals with type 2 diabetes who had HDL-C records (2008–2020) from the electronic health record database of the Hong Kong Hospital Authority. They were classified into three groups based on their first-recorded HDL-C levels following diabetes diagnosis: low (≤ 40 mg/dL), medium (> 40 and ≤ 80 mg/dL) and high HDL-C (> 80 mg/dL) groups. The primary outcome was incident MACE (composite of myocardial infarction, stroke, heart failure, and cardiovascular mortality). Cox regression model and restricted cubic spline analysis were employed to assess the relationship between HDL-C and adverse outcomes. Results: Among 596,943 individuals with type 2 diabetes included, 168,931 (28.30%), 412,863 (69.16%), and 15,149 (2.54%) were classified as low HDL-C, medium HDL-C, and high HDL-C groups, respectively. Over a median follow-up of 79.5 months, both low and high HDL-C groups had higher risk of incident MACE compared to the medium HDL-C group (HR 1.24, 95% CI 1.23–1.26, P < 0.001; HR 1.09, 95% CI 1.04–1.13, P < 0.001). The spline curves revealed a U-shaped association between HDL-C levels and incident MACE (non-linear p < 0.001). Similar U-shaped relationship was observed for all-cause and non-cardiovascular mortality. Conclusions: Our study demonstrated a U-shaped association between HDL-C levels and incident MACEs and all-cause and non-cardiovascular mortality in individuals with type 2 diabetes, highlighting the need for mechanistic studies on the adverse outcomes seen at high HDL-C levels in type 2 diabetes.

26 October 2022 in Drug Safety
Verified
Journal Article
Closed access
PDF file
DLDavid Tak Wai Lui
David Tak Wai Lui
TWTingting Wu
Tingting Wu
IAIvan Chi Ho Au
Ivan Chi Ho Au
XLXiaodong Liu
Xiaodong Liu
MFMatrix Man Him Fung
Matrix Man Him Fung
CWCarlos K H Wong
Carlos K H Wong

25 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
WCWing Lok Chan
Wing Lok Chan
XLXiaodong Liu
Xiaodong Liu
CWCarlos K H Wong
Carlos K H Wong
SWS. N. Michael Wong
S. N. Michael Wong
IWIan Yu-Hong Wong
Ian Yu-Hong Wong
DKDora LW Kwong
Dora LW Kwong
(1) Background: The effectiveness of adjuvant chemotherapy in older patients with gastric cancer after D2-gastrectomy is unclear. This study investigated the efficacy of adjuvant chemotherapy in elderly patients with stage II/III gastric cancer. (2) Methods: A real-world population-based retrospective cohort of patients aged ≥65 with stage II/III gastric cancer (n = 2616; median age: 73.5; 12.2% aged >80 years) treated between 1 January 1997 and 31 December 2020 were included. All data was retrieved from the Hong Kong Hospital Authority Clinical Management System (CMS). Clinical characteristics of those patients with and without adjuvant chemotherapy treatment were balanced after propensity score matching (PSM). In total, 732 patients treated with adjuvant chemotherapy were matched with 732 patients treated with surgery alone. Hazard ratios (HRs) estimated via Cox proportional hazards regression models were used to compare the overall survival (OS) and cancer-specific survival (CSS) of the two patient groups. (3) Results: Adjuvant chemotherapy was associated with better OS (37 vs. 25 months; HR: 0.80; 95% CI: 0.75–0.84; p < 0.001) than surgery alone. The OS benefit was observed in both the 65–80 (44 vs. 27 months; HR: 0.79; 95% CI: 0.74–0.84; p < 0.001) and >80 (14 vs. 11 months; HR: 0.82; 95% CI: 0.71–0.96; p < 0.001) age groups. A better CSS was observed in patients who received adjuvant chemotherapy than those who only had surgery (5-year CSS: 64.1% vs. 61.1%, HR: 0.85; 95% CI: 0.79–0.93; p < 0.001). (4) Conclusions: adjuvant chemotherapy significantly improved OS and CSS in older patients with stage II/III gastric cancer.

18 January 2024 in World Journal of Surgery
Verified
Journal Article
Open access
XLXiaodong Liu
Xiaodong Liu
CWCarlos K H Wong
Carlos K H Wong
TWTingting Wu
Tingting Wu
WCWing Lok Chan
Wing Lok Chan
YWYu Cho Woo
Yu Cho Woo
BLBrian H. H. Lang
Brian H. H. Lang
Objectives: This network meta‐analysis aimed to evaluate the association of anti‐thyroid drugs (ATD), radioactive iodine (RAI), and thyroidectomy with subsequent outcomes in patients with newly‐diagnosed hyperthyroidism.Methods: The Ovid Medline, Ovid Embase, and Cochrane Library databases were searched for observational studies and randomized controlled trials. Included studies were published on or before 1st May 2022 involving at least two of the treatments among ATD, RAI, and thyroidectomy for hyperthyroidism. Pairwise comparisons and Bayesian network meta‐analysis were used to estimate hazard ratios (HRs) and their credible interval (CrI) of outcomes, including cardiovascular disease (CVD), cancer, overall mortality, and Graves' ophthalmopathy (GO).Results: A total of 22 cohort studies with 131,297 hyperthyroidism patients were included. Thyroidectomy was associated with lower risks of mortality and GO than ATD (HR = 0.54, 95% CrI: 0.31, 0.96; HR = 0.31, 95% CrI: 0.12, 0.64) and RAI (HR = 0.62, 95% CrI: 0.41, 0.95; HR = 0.18, 95% CrI: 0.07, 0.35). RAI had a higher risk of GO (HR = 1.70, 95% CrI: 1.02, 2.99) than ATD treatment.Conclusions: This Bayesian network meta‐analysis indicated that thyroidectomy was associated with lower risks of mortality and GO in newly‐diagnosed hyperthyroid patients compared to ATD and RAI. Relative to ATD, RAI therapy increased the risk of GO.


2 February 2026 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
XXXi Xiong
Xi Xiong
DLDavid Tak Wai Lui
David Tak Wai Lui
CJChengsheng Ju
Chengsheng Ju
XLXiaodong Liu
Xiaodong Liu
LWLi Wei
Li Wei
CWCarlos K H Wong
Carlos K H Wong
Background: Type 2 diabetes is associated with an increased risk of fragility fractures. While obesity may protect against fractures, individuals with type 2 diabetes often exhibit other metabolic syndrome (MetS) traits and albuminuria. We evaluated their roles and synergistic implications on incident fractures, stratified by obesity status. Methods: Patients with type 2 diabetes were identified from territory‐wide electronic health records in Hong Kong (2000–2018). MetS‐related traits included albuminuria and individual MetS traits (obesity, hypertension, low HDL‐cholesterol and hypertriglyceridemia). Outcomes were hip and major osteoporotic fractures (MOF). Patients were followed until fracture, death or 31 December 2020. Adjusted hazard ratios (aHRs) were estimated using multivariable Cox models. Results: Among 165 289 patients with type 2 diabetes (median age: 60.0 years; 54.2% men), 1583 (0.96%) experienced hip fractures, and 3393 (2.05%) had MOF over a median follow‐up of 5.3 years. Albuminuria was the strongest risk factor for hip fractures (obese: aHR 1.33, 95% CI 1.11–1.60; non‐obese: 1.54, 1.33–1.78) and MOF (obese: 1.13, 1.01–1.26; non‐obese: 1.28, 1.15–1.43). Hypertension was a significant risk factor only in non‐obese patients. In the non‐obese group, each additional MetS‐related trait was associated with an increased risk of hip fracture and MOF. When stratified by diabetes duration, albuminuria remained a significant risk factor across different diabetes durations, while suboptimal glycaemic control became a significant risk factor particularly when diabetes duration ≥ 5 years. Conclusions: In this large population‐based cohort of patients with type 2 diabetes predominantly of Asian descent from Hong Kong, albuminuria emerged as an important predictor of fracture risk. MetS traits compound this risk, especially in non‐obese individuals. These findings could be instrumental in shaping screening initiatives for fracture risk optimization in type 2 diabetes.